Orally active MMP-1 sparing α-tetrahydropyranyl and α-piperidinyl Sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease

Journal of Medicinal Chemistry

Volumn 53, Issue 18, 2010, Pages 6653-6680

  Becker, Daniel P ^a   Barta, Thomas E ^a   Bedell, Louis J ^a   Boehm, Terri L ^a   Bond, Brian R ^a   Carroll, Jeffery ^a   Carron, Chris P ^a   Decrescenzo, Gary A ^a   Easton, Alan M ^a   Freskos, John N ^a   Funckes Shippy, Chris L ^a   Heron, Marcia ^a   Hockerman, Susan ^a   Howard, Carol Pearcy ^a   Kiefer, James R ^a   Li, Madeleine H ^a   Mathis, Karl J ^a   McDonald, Joseph J ^a   Mehta, Pramod P ^a   Munie, Grace E ^a   Sunyer, Teresa ^a   Swearingen, Craig A ^a   Villamil, Clara I ^a   Welsch, Dean ^a   Williams, Jennifer M ^a   Yu, Ying ^a   Yao, Jun ^a   more..

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 CYCLOPROPYL N HYDROXY 4 [4 [4 (TRIFLUOROMETHOXY)PHENOXY]PHENYLSULFONYL]PIPERIDINE 4 CARBOXAMIDE; CISPLATIN; COLLAGENASE 3; CYCLOPHOSPHAMIDE; GELATINASE A; GELATINASE B; HYDROXAMIC ACID DERIVATIVE; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE INHIBITOR; N HYDROXY 1 (2 METHOXYETHYL) 4 [[4 [4 (TRIFLUOROMETHOXY)PHENOXY]PHENYL]SULFONYL]PIPERIDINE 4 CARBOXAMIDE; N HYDROXY 4 [[4 [4 (TRIFLUOROMETHYL)PHENOXY]PHENYL]SULFONYL]TETRAHYDRO 2H PYRAN 4 CARBOXAMIDE; PIPERIDINE; SC 77774; SC 77964; SC 78080; SD 2590; UNCLASSIFIED DRUG; 1-CYCLOPROPYL-N-HYDROXY-4-(4-(4-(TRIFLUOROMETHOXY)PHENOXY)PHENYLSULFONYL)PIPERIDINE-4-CARBOXAMIDE; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; CARDIOVASCULAR AGENT; HYDROXAMIC ACID; N-HYDROXY-1-(2-METHOXYETHYL)-4-((4-(4-(TRIFLUOROMETHOXY)PHENOXY)PHENYL)SULFONYL)PIPERIDINE-4-CARBOXAMIDE; N-HYDROXY-4-((4-(4-(TRIFLUOROMETHYL)PHENOXY)PHENYL)SULFONYL)TETRAHYDRO-2H-PYRAN-4-CARBOXAMIDE; PIPERIDINE DERIVATIVE; PYRAN DERIVATIVE; SULFONE;

ARTICLE; BREAST CANCER; CANCER INHIBITION; CARDIOVASCULAR DISEASE; CARTILAGE DEGENERATION; CRYSTALLOGRAPHY; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; EX VIVO STUDY; HEART LEFT VENTRICLE HYPERTROPHY; NONHUMAN; OSTEOARTHRITIS; PROSTATE CANCER; TUMOR GROWTH; ANIMAL; ARTICULAR CARTILAGE; BIOAVAILABILITY; BOVINAE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; HUMAN; HYPERTROPHY, LEFT VENTRICULAR; MACACA FASCICULARIS; MOUSE; NUDE MOUSE; PATHOLOGY; RAT; STRUCTURE ACTIVITY RELATION; SYNTHESIS; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CARDIOVASCULAR AGENTS; CARTILAGE, ARTICULAR; CATTLE; CRYSTALLOGRAPHY, X-RAY; HUMANS; HYDROXAMIC ACIDS; HYPERTROPHY, LEFT VENTRICULAR; MACACA FASCICULARIS; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASES; MICE; MICE, NUDE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PIPERIDINES; PYRANS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONES; XENOGRAFT MODEL ANTITUMOR ASSAYS; MATRIX METALLOPROTEINASE INHIBITORS;

EID: 77956763130     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100669j     Document Type: Article

References (75)

1. Nagase, H.; Woessner, J. F., Jr. Matrix metalloproteinases J. Biol. Chem. 1999, 274, 21491-21494
2. Brinckerhoff, C. E.; Matrisian, L. M. Matrix metalloproteinases: a tail of a frog that became a prince Nat. Rev. Mol. Cell Biol. 2002, 3, 207-214
3. Gross, J.; Lapiere, C. M. Collagenolytic activity in amphibian tissues: a tissue-culture assay Pr0c. Natl. Acad. Sci. U.S.A. 1962, 48, 1014-1022
4. Fisher, J. F.; Mobashery, S. Recent advances in MMP inhibitor design Cancer Metastasis Rev. 2006, 25, 115-136
5. Corbitt, C. A.; Lin, J.; Lindsey, M. L. Mechanisms to inhibit matrix metalloproteinase activity: where are we in the development of clinically relevant inhibitors? Recent Pat. Anti-Cancer Drug Discovery 2007, 2, 135-142
6. John, A.; Tuszynski, G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis Pathol. Oncol. Res. 2001, 7, 14-23
7. Murphy, G.; Nagase, H. Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair? Nat. Clin. Pract. Rheumatol. 2008, 4, 128-135
8. Ishikawa, T.; Nishigaki, F.; Miyata, S.; Hirayama, Y.; Minoura, K.; Imanishi, J.; Neya, M.; Mizutani, T.; Imamura, Y.; Ohkubo, Y.; Mutoh, S. Prevention of progressive joint destruction in adjuvant induced arthritis in rats by a novel matrix metalloproteinase inhibitor, FR217840 Eur. J. Pharmacol. 2005, 508, 239-247 (Pubitemid 40169925)
9. Martel-Pelletier, J.; Welsch, D. J.; Pelletier, J. P. Metalloproteases and inhibitors in arthritic diseases Best Pract. Res., Clin. Rheumatol. 2001, 15, 805-829
10. MacFadyen, R. J. Can matrix metalloproteinase inhibitors provide a realistic therapy in cardiovascular medicine? Curr. Opin. Pharmacol. 2007, 7, 171-178
11. Lindsey, M. L. MMP Induction and Inhibition in Myocardial Infarction Heart Failure Rev. 2004, 9, 7-19
12. Peterson, J. T. Matrix Metalloproteinase Inhibitor Development and the Remodeling of Drug Discovery Heart Failure Rev. 2004, 9, 63-79
13. Ikejiri, M.; Bernardo, M. M.; Bonfil, R. D.; Toth, M.; Chang, M.; Fridman, R.; Mobashery, S. Potent mechanism-based inhibitors for matrix metalloproteinases J. Biol. Chem. 2005, 280, 33992-34002
14. Jacobsen, J. A.; Major Jourden, J. L.; Miller, M. T.; Cohen, S. M. To bind zinc or not to bind zinc: an examination of innovative approaches to improved metalloproteinase inhibition Biochim. Biophys. Acta, Mol. Cell Res. 2010, 1803, 72-94
15. Verma, R. P.; Hansch, C. Matrix metalloproteinases (MMPs): chemical-biological functions and QSARs Bioorg. Med. Chem. 2007, 15, 2223-2268
16. Skiles, J. W.; Gonnella, N. C.; Jeng, A. Y. The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors Curr. Med. Chem. 2004, 11, 2911-2977
17. Renkiewicz, R.; Qiu, L.; Lesch, C.; Sun, X.; Devalaraja, R.; Cody, T.; Kaldjian, E.; Welgus, H.; Baragi, V. Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats Arthritis Rheum. 2003, 48, 1742-1749
18. Freskos, J. N.; McDonald, J. J.; Mischke, B. V.; Mullins, P. B.; Shieh, H.; Stegeman, R. A.; Stevens, A. M. Synthesis and identification of conformationally constrained selective MMP inhibitors Bioorg. Med. Chem. Lett. 1999, 9, 1757-1760
19. Barta, T. E.; Becker, D. P.; Bedell, L. J.; DeCrescenzo, G. A.; McDonald, J. J.; Munie, G. E.; Rao, S.; Shieh, H.-S.; Stegeman, R.; Stevens, A. M.; Villamil, C. I. Synthesis and activity of selective MMP inhibitors with an aryl backbone Bioorg. Med. Chem. Lett. 2000, 10, 2815-2817
20. Chollet, A.-M.; Le Diguarher, T.; Murray, L.; Bertrand, M.; Tucker, G. C.; Sabatini, M.; Pierre, A.; Atassi, G.; Bonnet, J.; Casara, P. General synthesis of α-substituted 3-bis(aryloxy)propionic acid derivatives as specific MMP inhibitors Bioorg. Med. Chem. Lett. 2001, 11, 295-299
21. Reiter, L. A.; Robinson, R. P.; McClure, K. F.; Jones, C. S.; Reese, M. R.; Mitchell, P. G.; Otterness, I. G.; Bliven, M. L.; Liras, J.; Cortina, S. R.; Donahue, K. M.; Eskra, J. D.; Griffiths, R. J.; Lame, M. E.; Lopez-Anaya, A.; Martinelli, G. J.; McGahee, S. M.; Yocum, S. A.; Lopresti-Morrow, L. L.; Tobiassen, L. M.; Vaughn-Bowser, M. L. Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1 Bioorg. Med. Chem. Lett. 2004, 14, 3389-3395
22. Li, J.; Rush, T. S.; Li, W.; DeVincentis, D.; Du, X.; Hu, Y.; Thomason, J. R.; Xiang, J. S.; Skotnicki, J. S.; Tam, S.; Cunningham, K. M.; Chockalingam, P. S.; Morris, E. A.; Levin, J. I. Synthesis and SAR of highly selective MMP-13 inhibitors Bioorg. Med. Chem. Lett. 2005, 15, 4961-4966 (Pubitemid 41400165)
23. Schnute, M. E.; OBrien, P. M.; Nahra, J.; Morris, M.; Howard Roark, W.; Hanau, C. E.; Ruminski, P. G.; Scholten, J. A.; Fletcher, T. R.; Hamper, B. C.; Carroll, J. N.; Patt, W. C.; Shieh, H. S.; Collins, B.; Pavlovsky, A. G.; Palmquist, K. E.; Aston, K. W.; Hitchcock, J.; Rogers, M. D.; McDonald, J.; Johnson, A. R.; Munie, G. E.; Wittwer, A. J.; Man, C.; Settle, S. L.; Nemirovskiy, O.; Vickery, L. E.; Agawal, A.; Dyer, R. D.; Sunyer, T. Discovery of (pyridin-4-yl)-2 H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis Bioorg. Med. Chem. Lett. 2010, 20, 576-580
24. Whitlock, G. A.; Dack, K. N.; Dickinson, R. P.; Lewis, M. L. A novel series of highly selective inhibitors of MMP-3 Bioorg. Med. Chem. Lett. 2007, 17, 6750-6753
25. Freeman-Cook, K. D.; Reiter, L. A.; Noe, M. C.; Antipas, A. S.; Danley, D. E.; Datta, K.; Downs, J. T.; Eisenbeis, S.; Eskra, J. D.; Garmene, D. J.; Greer, E. M.; Griffiths, R. J.; Guzman, R.; Hardink, J. R.; Janat, F.; Jones, C. S.; Martinelli, G. J.; Mitchell, P. G.; Laird, E. R.; Liras, J. L.; Lopresti-Morrow, L. L.; Pandit, J.; Reilly, U. D.; Robertson, D.; Vaughn-Bowser, M. L.; Wolf-Gouviea, L. A.; Yocum, S. A. Potent, selective spiropyrrolidine pyrimidinetrione inhibitors of MMP-13 Bioorg. Med. Chem. Lett. 2007, 17, 6529-6534
26. Pirard, B. Insight into the structural determinants for selective inhibition of matrix metalloproteinases Drug Discovery Today 2007, 12, 640-646
27. Bramhall, S. R.; Hallissey, M. T.; Whiting, J.; Scholefield, J.; Tierney, G.; Stuart, R. C.; Hawkins, R. E.; McCulloch, P.; Maughan, T.; Brown, P. D.; Baillet, M.; Fielding, J. W. L. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial Br. J. Cancer 2002, 86, 1864-1870
28. Bramhall, S. R.; Rosemurgy, A.; Brown, P. D.; Bowry, C.; Buckels, J. A. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial J. Clin. Oncol. 2001, 19, 3447-3455
29. Groves, M. D.; Puduvalli, V. K.; Hess, K. R.; Jaeckle, K. A.; Peterson, P.; Yung, W. K. A.; Levin, V. A. Phase II trial of Temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme J. Clin. Oncol. 2002, 20, 1383-1388
30. Sparano, J. A.; Bernardo, P.; Stephenson, P.; Gradishar, W. J.; Ingle, J. N.; Zucker, S.; Davidson, N. E. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group Trial E2196 J. Clin. Oncol. 2004, 22, 4683-4690
31. Lara, P. N., Jr.; Stadler, W. M.; Longmate, J.; Quinn, D. I.; Wexler, J.; Van Loan, M.; Twardowski, P.; Gumerlock, P. H.; Vogelzang, N. J.; Vokes, E. E.; Lenz, H. J.; Doroshow, J. H.; Gandara, D. R. A randomized phase II Trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases Clin. Cancer Res. 2006, 12, 1556-1563
32. Brinker, B. T.; Krown, S. E.; Lee, J. Y.; Cesarman, E.; Chadburn, A.; Kaplan, L. D.; Henry, D. H.; Von Roenn, J. H. Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS malignancy consortium Cancer (Hoboken, NJ, U.S.) 2008, 112, 1083-1088
33. Miller, K. D.; Saphner, T. J.; Waterhouse, D. M.; Chen, T.-T.; Rush-Taylor, A.; Sparano, J. A.; Wolff, A. C.; Cobleigh, M. A.; Galbraith, S.; Sledge, G. W. A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer Clin. Cancer Res. 2004, 10, 1971-1975
34. Bissett, D.; OByrne, K. J.; von Pawel, J.; Gatzemeier, U.; Price, A.; Nicolson, M.; Mercier, R.; Mazabel, E.; Penning, C.; Zhang, M. H.; Collier, M. A.; Shepherd, F. A. Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer J. Clin. Oncol. 2005, 23, 842-849
35. Hudson, M. P.; Armstrong, P. W.; Ruzyllo, W.; Brum, J.; Cusmano, L.; Krzeski, P.; Lyon, R.; Quinones, M.; Theroux, P.; Sydlowski, D.; Kim, H. E.; Garcia, M. J.; Jaber, W. A.; Weaver, W. D. Effects of Selective Matrix Metalloproteinase Inhibitor (PG-116800) to Prevent Ventricular Remodeling After Myocardial Infarction J. Am. Coll. Cardiol. 2006, 48, 15-20
36. Yarbrough, W. M.; Mukherjee, R.; Escobar, G. P.; Mingoia, J. T.; Sample, J. A.; Hendrick, J. W.; Dowdy, K. B.; McLean, J. E.; Lowry, A. S.; ONeill, T. P.; Spinale, F. G. Selective Targeting and Timing of Matrix Metalloproteinase Inhibition in Post-Myocardial Infarction Remodeling Circulation 2003, 108, 1753-1759 (Pubitemid 37243666)
37. Krzeski, P.; Buckland-Wright, C.; Balint, G.; Cline, G. A.; Stoner, K.; Lyon, R.; Beary, J.; Aronstein, W. S.; Spector, T. D. Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study Arthritis Res. Ther. 2007, 9, R109
38. Becker, D. P.; Barta, T. E.; Bedell, L.; DeCrescenzo, G.; Freskos, J.; Getman, D. P.; Hockerman, S. L.; Li, M.; Mehta, P.; Mischke, B.; Munie, G. E.; Swearingen, C.; Villamil, C. I. R-Amino-α-sulphone hydroxamates as potent MMP-13 inhibitors that spare MMP-1 Bioorg. Med. Chem. Lett. 2001, 11, 2719-2722. (Pubitemid 32925302)
39. Becker, D. P.; DeCrescenzo, G.; Freskos, J.; Getman, D. P.; Hockerman, S. L.; Li, M.; Mehta, P.; Munie, G. E.; Swearingen, C. R-Alkyl-R-amino-α- sulphone hydroxamates as potent MMP inhibitors that spare MMP-1. Bioorg. Med. Chem. Lett. 2001, 11, 2723-2725. (Pubitemid 32925303)
40. Lollini, L.; Haller, J.; Eugui, E. M.; Womble, S. W.; Martin, R.; Campbell, J. Disease modification by RS-130830, a collagenase-3 selective inhibitor, in experimental osteoarthritis (OA) Arthritis Rheum. 1997, 40 (Suppl S87) 341
41. Close, D. R. Matrix metalloproteinase inhibitors in rheumatic diseases Ann. Rheum. Dis. 2001, 60, iii62-iii67
42. Becker, D. P.; Villamil, C. I.; Barta, T. E.; Bedell, L. J.; Boehm, T. L.; DeCrescenzo, G. A.; Freskos, J. N.; Getman, D. P.; Hockerman, S.; Heintz, R.; Howard, S. C.; Li, M. H.; McDonald, J. J.; Carron, C. P.; Funckes-Shippy, C. L.; Mehta, P. P.; Munie, G. E.; Swearingen, C. A. Synthesis and structure-activity relationships of β-and α-piperidine sulfone hydroxamic acid matrix metalloproteinase inhibitors with oral antitumor efficacy J. Med. Chem. 2005, 48, 6713-6730
43. Samaritoni, J. G.; Babbitt, G. E. Synthesis of 2-(4-quinazolinyl)ethyl sulfides via addition of thiols to 4-vinylquinazolines J. Heterocycl. Chem. 1997, 34, 1263-1266
44. Kolodziej, S. A.; Hockerman, S. L.; Boehm, T. L.; Carroll, J. N.; DeCrescenzo, G. A.; McDonald, J. J.; Mischke, D. A.; Munie, G. E.; Fletcher, T. R.; Rico, J. G.; Stehle, N. W.; Swearingen, C.; Becker, D. P. Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective α-sulfone hydroxamates Bioorg. Med. Chem. Lett. 2010, 20, 3557-3560
45. Kolodziej, S. A.; Hockerman, S. L.; DeCrescenzo, G. A.; McDonald, J. J.; Mischke, D. A.; Munie, G. E.; Fletcher, T. R.; Stehle, N.; Swearingen, C.; Becker, D. P. MMP-13 selective isonipecotamide α-sulfone hydroxamates Bioorg. Med. Chem. Lett. 2010, 20, 3561-3564
46. van de Waterbeemd, H.; Testa, B. In Drug Bioavailability: Estimation of Solubility, Permeability, Absorption and Bioavailability; Strauss GmbH: Mörlenbach, Germany, 2009; pp 458.
47. Silverman, R. B. Lead Modification: Drug Design and Development. In The Organic Chemistry of Drug Design and Drug Action; Elsevier Academic Press: New York, 2004; pp 62-65.
48. Mistryukov, E. A.; Aronova, N. I. Basicity of amines of the piperidine series and dependence of basicity on steric and polar factors Izv. Akad. Nauk SSSR, Ser. Khim. 1967, 789-793
49. Gillaspy, M.; Lefker, B. A.; Hada, W. A.; Hoover, D. J. A simple method for the formation of cyclopropylamines: the first synthesis of tricyclopropylamine Tetrahedron Lett. 1995, 36, 7399-7402
50. Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. DrugBank: a knowledgebase for drugs, drug actions and drug targets Nucleic Acids Res. 2008, 36, D901-D906
51. Kageyama, S.; Anderson, B. D.; Hoesterey, B. L.; Hayashi, H.; Kiso, Y.; Flora, K. P.; Mitsuya, H. Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins Antimicrob. Agents Chemother. 1994, 38, 1107-1111
52. Hagmann, W. K. The Many Roles for Fluorine in Medicinal Chemistry J. Med. Chem. 2008, 51, 4359-4369
53. Lovejoy, B.; Cleasby, A.; Hassell, A. M.; Luther, M. A.; Weigl, D.; McGeehan, G.; Lambert, M. H.; Jordan, S. R. Structural analysis of the catalytic domain of human fibroblast collagenase Ann. N.Y. Acad. Sci. 1994, 732, 375-378
54. Borkakoti, N.; Winkler, F. K.; Williams, D. H.; DArcy, A.; Broadhurst, M. J.; Brown, P. A.; Johnson, W. H.; Murray, E. J. Structure of the catalytic domain of human fibroblast collagenase complexed with an inhibitor Nat. Struct. Biol. 1994, 1, 106-110
55. Lovejoy, B.; Welch, A. R.; Carr, S.; Luong, C.; Broka, C.; Hendricks, R. T.; Campbell, J. A.; Walker, K. A. M.; Martin, R.; Van Wart, H.; Browner, M. F. Crystal structures of MMP-1 and-13 reveal the structural basis for selectivity of collagenase inhibitors Nature Struct. Biol. 1999, 6, 217-221
56. Howard, J. A. K.; Hoy, V. J.; OHagan, D.; Smith, G. T. How good is fluorine as a hydrogen bond acceptor? Tetrahedron 1996, 52, 12613-12622
57. Shalinsky, D. R.; Brekken, J.; Zou, H.; McDermott, C. D.; Forsyth, P.; Edwards, D.; Margosiak, S.; Bender, S.; Truitt, G.; Wood, A.; Varki, N. M.; Appelt, K. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials Ann. N.Y. Acad. Sci. 1999, 878, 236-270
58. Bottomley, K. M.; Borkakoti, N.; Bradshaw, D.; Brown, P. A.; Broadhurst, M. J.; Budd, J. M.; Elliott, L.; Eyers, P.; Hallam, T. J.; Handa, B. K.; Hill, C. H.; James, M.; Lahm, H.; Lawton, G.; Merritt, J. E.; Nixon, J. S.; Rothlisberger, U.; Whittle, A.; Johnson, W. H. Inhibition of bovine nasal cartilage degradation by selective matrix metalloproteinase inhibitors Biochem. J. 1997, 323, 483-488
59. Billinghurst, R. C.; Dahlberg, L.; Ionescu, M.; Reiner, A.; Bourne, R.; Rorabeck, C.; Mitchell, P.; Hambor, J.; Diekmann, O.; Tschesche, H.; Chen, J.; Van Wart, H.; Poole, A. R. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage J. Clin. Invest. 1997, 99, 1534-1545
60. Pfeffer, M. A.; Pfeffer, J. M.; Fishbein, M. C.; Fletcher, P. J.; Spadaro, J.; Kloner, R. A.; Braunwald, E. Myocardial infarct size and ventricular function in rats Circ. Res. 1979, 44, 503-512
61. Fletcher, P. J.; Pfeffer, J. M.; Pfeffer, M. A.; Braunwald, E. Left ventricular diastolic pressure-volume relations in rats with healed myocardial infarction. Effects on systolic function Circ. Res. 1981, 49, 618-626
62. Holmbeck, K.; Bianco, P.; Caterina, J.; Yamada, S.; Kromer, M.; Kuznetsov, S. A.; Mankani, M.; Robey, P. G.; Poole, A. R.; Pidoux, I.; Ward, J. M.; Birkedal-Hansen, H. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover Cell (Cambridge, MA, U. S.) 1999, 99, 81-92
63. Zhou, Z.; Apte, S. S.; Soininen, R.; Cao, R.; Baaklini, G. Y.; Rauser, R. W.; Wang, J.; Cao, Y.; Tryggvason, K. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 4052-4057
64. Devy, L.; Huang, L.; Naa, L.; Yanamandra, N.; Pieters, H.; Frans, N.; Chang, E.; Tao, Q.; Vanhove, M.; Lejeune, A.; van Gool, R.; Sexton, D. J.; Kuang, G.; Rank, D.; Hogan, S.; Pazmany, C.; Ma, Y. L.; Schoonbroodt, S.; Nixon, A. E.; Ladner, R. C.; Hoet, R.; Henderikx, P.; TenHoor, C.; Rabbani, S. A.; Valentino, M. L.; Wood, C. R.; Dransfield, D. T. Selective Inhibition of Matrix Metalloproteinase-14 Blocks Tumor Growth, Invasion, and Angiogenesis Cancer Res. 2009, 69, 1517-1526
65. Vora, R. A.; Vyas, P. R. Mesogenic homologous series: 4-isopropoxyphenyl 4′-n-alkoxycinnamates and binary systems comprising the homologs of this series J. Indian Chem. Soc. 1996, 73, 507-511
66. DeCrescenzo, G. A.; Rico, J. G.; Boehm, T. L.; Carroll, J. N.; Kassab, D. J.; Mischke, D. A.; Rao, S. Sulfamato hydroxamic acid metalloprotease inhibitor. U.S. Patent 6,448,250, 2000.
67. Otwinowski, Z.; Minor, W. Processing of X-ray diffraction data collected in oscillation mode Methods Enzymol. 1997, 276, 307-326
68. Jones, T. A.; Zou, J. Y.; Cowan, S. W.; Kjeldgaard, M. Improved methods for building protein models in electron density maps and the location of errors in these models Acta Crystallogr., Sect. A: Found. Crystallogr. 1991, 47, 110-119
69. Emsley, P.; Cowtan, K. Coot: model-building tools for molecular graphics Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 2126-2132
70. Brunger, A. T.; Free, R Free R value: a novel statistical quantity for assessing the accuracy of crystal structures Nature 1992, 355, 472-475
71. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr., Sect. D: Biol. Crystallogr. 1997, 53, 240-255
72. Nagase, H.; Fields, C. G.; Fields, G. B. Design and characterization of a fluorogenic substrate selectively hydrolyzed by stromelysin 1 (matrix metalloproteinase-3) J. Biol. Chem. 1994, 269, 20952-20957
73. Knight, C. G.; Willenbrock, F.; Murphy, G. A novel coumarin-labeled peptide for sensitive continuous assays of the matrix metalloproteinases FEBS Lett. 1992, 296, 263-266
74. Luckow, V. A. Insect Cell Expression Technology. In Protein Engineering: Principles and Practice; John Wiley & Sons: New York, 1996; pp 183-218.
75. Luckow, V. A.; Lee, S. C.; Barry, G. F.; Olins, P. O. Efficient generation of infectious recombinant baculoviruses by site-specific transposon-mediated insertion of foreign genes into a baculovirus genome propagated in Escherichia coli J. Virol. 1993, 67, 4566-4579